Clinical Evidence for Dual-Peptide Weight Loss Therapy Published data on GLP-1 monotherapy shows average weight loss of 1522% over 68 weeks in phase 3 trials, with sustained improvements in waist circumference and cardiometabolic markers
Researchers had hypothesized that harnessing GLP-1 could lead to effective treatments for type 2 diabetes, while offering benefits like weight loss and lower hypoglycemia risks as well
Muscles need several things to work properly: Glucose (sugar) from the food we eat provides energy
SAlk: Writing original draft, Investigation, Resources, Formal analysis, Visualization, Conceptualization, Data curation, Validation, Writing review & editing
Additionally, the psychological stress associated with being unwell or anxious about one's health can impact sexual performance